

Support of RWE in the Price and Reimbursement Decision-Making Process for Rare Diseases in Spain

AUTHORS

De la Paz Cañizares, Isabel
Engagement Manager, Alira Health
isabel.delapaz@alirahealth.com

Saborido, Carlos Martín
Instituto de Salud Carlos III

Calleja, Miguel Ángel
University Hospital Virgen Macarena

Sala Piñol, Ferrán
Institut Català de la Salut

Asensio, Irene
Alira Health

Castillo, Chus
Partner, Alira Health
chus.castillo@alirahealth.com

Fontanet, Manel
CatSalut

Martínez Sesmero, José M.
Ciudad Real General University Hospital

Hernaez Colque, Mariana
Alira Health

Ferrández, Oriol
Alira Health



BACKGROUND AND OBJECTIVES

Background: Real-world data (RWD) is a promising source of complementary evidence to accelerate drug access in rare diseases (RDs). However, real-world evidence (RWE) applicability in RDs' price and reimbursement (P&R) decision-making is still limited.


Objective: Define how RWE can support the P&R decision-making process to accelerate drug access for RDs in Spain.



RESULTS

14¹⁻¹⁴ studies and 127 reports (56 TPRs¹⁵⁻⁷⁰, 56 EPAR⁷¹⁻¹²⁶, and 15¹²⁷⁻¹⁴¹ regional evaluations) were included.

PRISMA diagram




Date of search: May 10th, 2023
EPAR: European public assessment report; TPR: therapeutic positioning report
¹Timeframe: 2018 – 2023; ²TPRs on RDs published between 2018-2023 and corresponding EPARs and regional evaluations.

- > Currently, RWE has a minor impact on the P&R decision-making for RDs in Spain, limited to a supporting tool for outcome-based agreements
- > RWE can play a key role in establishing innovative dynamic and value-based pricing strategies (currently under evaluation in Spain) and in re-evaluation processes and price reviews
- > Key points to consider RWE in P&R decisions include an early dialogue with payers to co-create the most suitable study design that addresses payers' uncertainties and to include RWE studies within the evidence generation plan
- > Main challenges to overcome include a commitment from the public administration to set a framework for the use and applicability of RWE, commitment from pharmaceutical companies to publish generated evidence; transparency of the decision-making process; application of technologies to extract the RWD from primary sources; and data governance



CONCLUSION

Beyond its current limited use, RWE can serve as a tool facilitating dynamic and value-based pricing agreements to accelerate the P&R process and thereby the access to new RDs drugs to patients.




METHODOLOGY

A targeted literature review (TLR) of articles and reports published between 2018-2023 to examine RWE utilization in the P&R process for RDs drugs was conducted, followed by a focus group primary market research with Spanish payers to validate literature findings and address the identified gaps.

The TLR included articles covering uncertainties, perception, and use of RWE in the P&R process. TPRs (therapeutic positioning reports) on RDs and their corresponding EPARs (European Medicine Assessment Reports) and regional evaluations were searched and included.

RWE studies in TPRs and corresponding EPARs



EPAR: European public assessment report; TPR: therapeutic positioning report; RWE: real world evidence
¹Studies on the disease, epidemiology, efficacy, and/or safety (short-term or long-term) of the investigational drug or therapeutic alternatives or competitors; ²Upon request by the EMA or at the promoter's proposal.

Key insight	Rationale
RWE has a minor impact on the P&R decision-making for RDs	> RWE has not impacted price or decision-making of RDs in Spain; when TPRs refer to RWE studies, is mainly contextual > There is a lack of definition of the value of RWE in the health technology assessment and P&R decision-making
RWE can play a key role in establishing innovative dynamic and value-based pricing strategies	> VALTERMED and early access programs have the potential to generate RWD that can be exploited for evidence generation > RWE complements the evidence needed in P&R decisions, can act as a supporting tool for outcome-based agreements, and for the establishment of dynamic pricing strategies > New generated evidence should translate into changes in drug pricing and positioning > Dynamic pricing strategies must be agreed from the beginning of the P&R negotiation > RWE could be key in drug re-evaluation if the evidence supports the value of the drug, and to ensure real-life drug effectiveness; although currently re-evaluation processes often results in a price decrease
Key points to consider RWE in P&R decisions	> Early dialogue with payers to ensure that RWE studies' objective cover uncertainties that arise at the time of the negotiation, not covered by the evidence generated in clinical trials > Studies must have a robust study design that will be accepted by the authorities (following guidelines, registered protocols, etc) > Early Dialogue Advice with regulatory and Health Technologies Assessment agencies must be encouraged > RWE generation should be considered early in the drug development plan (to be available at the P&R process)
Main challenges of including RWE in P&R decisions	> Commitment and transparency from all parties > Apply new technologies (such as AI) to extract data > Data quality (preference for primary sources) and governance > Replication of clinical trial conditions and concerns about RWE studies methodology



DOWNLOAD THE DIGITAL VERSION AND REFERENCES

Scan this QR code to download a copy of the poster.

Please note that reproducing copies of this poster and additional content via the Quick Response (QR) code is prohibited without permission from the authors.

